PE19372014A1 - Methods of treating disorders related to elimination viii mutant epidermal growth factor - Google Patents

Methods of treating disorders related to elimination viii mutant epidermal growth factor

Info

Publication number
PE19372014A1
PE19372014A1 PE2014000701A PE0007012014A PE19372014A1 PE 19372014 A1 PE19372014 A1 PE 19372014A1 PE 2014000701 A PE2014000701 A PE 2014000701A PE 0007012014 A PE0007012014 A PE 0007012014A PE 19372014 A1 PE19372014 A1 PE 19372014A1
Authority
PE
Peru
Prior art keywords
growth factor
epidermal growth
disorders related
treating disorders
elimination
Prior art date
Application number
PE2014000701A
Other languages
Spanish (es)
Inventor
John Stephen Hill
Kevin J Hamblett
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161560731P priority Critical
Priority to US201261727029P priority
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE19372014A1 publication Critical patent/PE19372014A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Abstract

SE REFIERE A UN METODO PARA TRATAR TRASTORNOS RELACIONADOS CON MUTANTE VIII (EGFRVIII) DE ELIMINACION DE FACTOR DE CRECIMIENTO EPIDERMICO, QUE SE CARACTERIZA PORQUE COMPRENDE ADMINISTRAR UN CONJUGADO DE ANTICUERPO FARMACO ANTI-EGFRVIII. It REFERS TO A METHOD FOR TREATING DISORDERS RELATED TO MUTANT VIII (EGFRvIII) DISPOSAL epidermal growth factor, characterized in that comprises administering an antibody DRUG ANTI-EGFRvIII. DICHO ANTICUERPO DEL CONJUGADO COMPRENDE UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEQ ID NO 2 Y UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE LA SECUENCIA DE AMINOACIDO SEQ ID NO 19. OF THE CONJUGATE said antibody comprises a region VARIABLE heavy chain comprising amino acid sequence of SEQ ID NO 2 VARIABLE REGION AND A light chain comprising amino acid sequence SEQ ID NO 19.
PE2014000701A 2011-11-16 2012-11-16 Methods of treating disorders related to elimination viii mutant epidermal growth factor PE19372014A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161560731P true 2011-11-16 2011-11-16
US201261727029P true 2012-11-15 2012-11-15

Publications (1)

Publication Number Publication Date
PE19372014A1 true PE19372014A1 (en) 2014-12-18

Family

ID=47258124

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000701A PE19372014A1 (en) 2011-11-16 2012-11-16 Methods of treating disorders related to elimination viii mutant epidermal growth factor

Country Status (21)

Country Link
US (1) US20140314667A1 (en)
EP (1) EP2780040A1 (en)
JP (1) JP2015500205A (en)
KR (1) KR20140091064A (en)
CN (1) CN104168922A (en)
AP (1) AP201407638A0 (en)
AU (1) AU2012340174A1 (en)
BR (1) BR112014011912A2 (en)
CA (1) CA2855746A1 (en)
CL (1) CL2014001299A1 (en)
CO (1) CO6980620A2 (en)
CR (1) CR20140267A (en)
EA (1) EA201490974A1 (en)
HK (1) HK1202252A1 (en)
IL (1) IL232497D0 (en)
MX (1) MX2014005957A (en)
PE (1) PE19372014A1 (en)
PH (1) PH12014501103A1 (en)
SG (1) SG11201402365RA (en)
WO (1) WO2013075048A1 (en)
ZA (1) ZA201403541B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4800210B2 (en) 2003-06-27 2011-10-26 アムジエン・フレモント・インコーポレイテツド Antibodies that recognize deletion mutants of epidermal growth factor receptor and uses thereof
CN105188766B (en) 2013-03-15 2019-07-12 瑞泽恩制药公司 Bioactive molecule, its conjugate and therapeutical uses
US10358494B2 (en) 2013-05-03 2019-07-23 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
CN105473616A (en) * 2013-07-05 2016-04-06 形成生物产品有限公司 Antibody conjugate Egfr
JP2018501783A (en) * 2014-11-25 2018-01-25 ファームアブシン インコーポレイテッドPharmabcine Inc. Novel EGFRvIII antibody and composition containing the same
WO2016134371A2 (en) * 2015-02-20 2016-08-25 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
WO2017142294A1 (en) * 2016-02-15 2017-08-24 사회복지법인 삼성생명공익재단 ANTIBODY AGAINST EGFRvIII AND USE THEREOF

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
EP0052322B1 (en) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
JPH0368506B2 (en) 1982-03-29 1991-10-28 Tokyo Shibaura Electric Co
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar Peter Dr Ing Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (en) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense.
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
JPH0368180B2 (en) 1986-01-22 1991-10-25 Shisutemu Mentenansu Kk
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
AU650629B2 (en) 1989-08-09 1994-06-30 Rhomed Incorporated Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073B1 (en) 1990-06-29 1995-03-31 Thomson Csf
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. Transgenic non-human animals able to produce heterological antibodies.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AT352612T (en) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologous recombination in mammalian cells
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int Methods for producing transgenic non-human animals harboring a yeast artificial chromosome.
US5372783A (en) 1992-08-03 1994-12-13 Sapidyne, Inc. Assay system
US5958708A (en) 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
DE69636868T2 (en) 1995-08-29 2007-10-25 Kirin Beer Kabushiki Kaisha Chimeric animal and method for the production thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK0942968T3 (en) 1996-12-03 2008-06-23 Amgen Fremont Inc Fully human antibodies that bind EGFR
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
NZ520622A (en) 2000-02-25 2004-08-27 Us Gov Health & Human Serv Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US7754433B2 (en) 2001-12-03 2010-07-13 Amgen Fremont Inc. Identification of high affinity molecules by limited dilution screening
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
JP4800210B2 (en) * 2003-06-27 2011-10-26 アムジエン・フレモント・インコーポレイテツド Antibodies that recognize deletion mutants of epidermal growth factor receptor and uses thereof
CN1930187B (en) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 Mutant antibodies and their use thereof for the absence of epidermal growth factor receptor
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7064994B1 (en) 2004-01-30 2006-06-20 Sun Microsystems, Inc. Dynamic memory throttling for power and thermal limitations
KR20060131892A (en) 2004-02-16 2006-12-20 마이크로메트 에이지 Less immunogenic binding molecules
WO2006034035A2 (en) 2004-09-16 2006-03-30 Virogenomics, Inc. Treatment of ischemia
ES2616316T3 (en) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Compositions comprising specific antibodies for different species and uses thereof
JP6071725B2 (en) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 Driving force control device for electric vehicles

Also Published As

Publication number Publication date
EP2780040A1 (en) 2014-09-24
PH12014501103A1 (en) 2014-10-20
CR20140267A (en) 2014-08-27
ZA201403541B (en) 2015-12-23
AP201407638A0 (en) 2014-05-31
CO6980620A2 (en) 2014-06-27
JP2015500205A (en) 2015-01-05
SG11201402365RA (en) 2014-06-27
HK1202252A1 (en) 2015-09-25
WO2013075048A1 (en) 2013-05-23
EA201490974A1 (en) 2014-09-30
MX2014005957A (en) 2015-02-04
CA2855746A1 (en) 2013-05-23
CN104168922A (en) 2014-11-26
KR20140091064A (en) 2014-07-18
BR112014011912A2 (en) 2017-05-16
US20140314667A1 (en) 2014-10-23
AU2012340174A1 (en) 2014-05-29
CL2014001299A1 (en) 2014-10-10
IL232497D0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
SI2719708T1 (en) Material and methods for treating or preventing HER-3 associated diseases
UY31747A (en) New formulations, tablets comprising such formulations, use and process for their preparation
MY160499A (en) Anti-cd38 antibodies
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
NZ590033A (en) Interleukin-1alpha antibodies and methods of use
CL2011001361A1 (en) Compounds derived n- (imidazo [1,2-a] pyrazin-8-yl) -1H-amine; pharmaceutical composition which comprises; and their use in treating diseases mediated by syk activity inhiibicion of such as cancer, allergic or inflammatory disorders.
MX2012004258A (en) Inhibitors of bruton's tyrosine kinase.
CL2010001427A1 (en) Binding protein comprising a polypeptide chain capable of binding a pair of antigens; isolated nucleic acid encoding said binding protein; vector and host cell; method for producing binding protein; pharmaceutical composition comprising said protein.
UY34453A (en) Binding molecules for bcma and cd3
CU20110029A7 (en) Compositions and methods for antibodies directed to the complement protein c5
CO6190543A2 (en) Anti-factor d Humanized
DOP2015000051A (en) stable aqueous formulations of adalimumab
AR106702A2 (en) Use of an anti-NGF antagonist antibody for the preparation of a medicament
DOP2013000128A (en) Using T cells modified with a chimeric antigen receptor for treating cancer
PE06142014A1 (en) anti-CD79b antibodies and immunoconjugates
CR20110639A (en) Mutants FGF21 and uses thereof
TR201816421T4 (en) Compounds for kinase modulation and methods and their indications.
CR8978A (en) Fusion proteins binding domain
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
PE14782008A1 (en) CD44 antibodies
CU24097B1 (en) pyridyloxy-substituted compounds Indoles as inhibitors of VEGF-R2 useful for the treatment of proliferative diseases
NO20082907L (en) The process feed of using IL-6 antagonists with proteasome inhibitors
BR112014007721A2 (en) processes for preparing compounds useful as atrinase inhibitors
CO6230999A2 (en) Anti-sclerostin antibody
UA96922C2 (en) Il-12/p40 binding protein

Legal Events

Date Code Title Description
FD Application declared void or lapsed